Neuphoria Therapeutics Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Neuphoria Therapeutics Inc. (NEUP) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $14.03 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-09-18
- Neuphoria Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-09-30 was -$19.45K, a 114.06% decline year-over-year.
- Neuphoria Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-09-30 was $138.37K.
- Neuphoria Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-09-30 was -$152.77K.
- Neuphoria Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2026 was $14.03K.
- Neuphoria Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was -$3.75K, a 104.87% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was $76.97K.
- Neuphoria Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$243.82K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.03K 10-K · filed 2026-09-18 | |||
| 2026-03-31 | $803.01K 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $275.95K 10-Q · filed 2026-02-17 | |||
| 2025-09-30 | -$19.45K 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$3.75K 10-K · filed 2026-09-18 | |||
| 2025-03-31 | -$53.36K 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$138.32K 10-Q · filed 2026-02-17 | |||
| 2024-09-30 | $138.37K 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $76.97K 10-K · filed 2025-09-29 | |||
| 2024-03-31 | $4.61K 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | $190.47K 10-Q · filed 2025-02-14 | |||
| 2023-09-30 | -$152.77K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$243.82K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |